<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348503</url>
  </required_header>
  <id_info>
    <org_study_id>1004-05; IUCRO-0298</org_study_id>
    <nct_id>NCT01348503</nct_id>
  </id_info>
  <brief_title>Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma</brief_title>
  <official_title>A Phase I Open-label Dose-escalation Study With Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the combination of Revlimid速 (lenalidomide) and&#xD;
      Nexavar速 (sorafenib) for the treatment of hepatocellular carcinoma that can't be cured with&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Treatment was ineffective&#xD;
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicities as a Measure of Safety of the combination of lenalidomide and sorafenib.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Open Label, Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of lenalidomide in combination with sorafenib at standard doses in patients with advanced, unresectable hepatocellular carcinoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Escalating doses starting at 15 mg by mouth per day.</description>
    <arm_group_label>Open Label, Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Fixed dose of 400 mg by mouth twice a day.</description>
    <arm_group_label>Open Label, Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical or pathological diagnosis of unresectable hepatocellular carcinoma (HCC)&#xD;
             based on radiologic criteria, elevated alpha fetoprotein and/or tissue biopsy&#xD;
&#xD;
          -  All previous cancer therapy, including radiation, hormonal therapy and surgery, must&#xD;
             have been discontinued at least 28 days prior to treatment in this study&#xD;
&#xD;
          -  Child-Pugh Liver Function Class A/B9&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of &lt;/= 2 at study entry&#xD;
&#xD;
          -  Laboratory test results within protocol-specific ranges&#xD;
&#xD;
          -  Disease free of prior malignancies for &gt;/= 5 years with exception of currently treated&#xD;
             basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of the cervix&#xD;
             or breast.&#xD;
&#xD;
          -  All study participants must be registered into the mandatory RevAssist速 program, and&#xD;
             be willing and able to comply with the requirements of RevAssist速 (Revlimid is only&#xD;
             available under a restricted distribution program called &quot;RevAssist.&quot;)&#xD;
&#xD;
          -  Females of childbearing potential must have two negative pregnancy tests before&#xD;
             starting lenalidomide and must agree to use two methods of birth control and submit to&#xD;
             pregnancy tests throughout the study.&#xD;
&#xD;
          -  Able to take aspirin daily as prophylactic anticoagulation&#xD;
&#xD;
          -  Age &gt;18 years at the time of signing the informed consent form&#xD;
&#xD;
          -  Life expectancy of at least 30 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No serious medical condition, laboratory abnormality, or psychiatric illness&#xD;
             (including no evidence of hepatic encephalopathy) that would prevent the subject from&#xD;
             signing the informed consent form&#xD;
&#xD;
          -  No pregnant or breast feeding females. (Lactating females must agree not to breast&#xD;
             feed while taking lenalidomide)&#xD;
&#xD;
          -  No patients who have undergone surgical resection or received chemotherapy,&#xD;
             percutaneous ethanol injection, radiation therapy or chemoembolization within 30 days&#xD;
             prior to commencement of the study&#xD;
&#xD;
          -  No condition, including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study or confounds&#xD;
             the ability to interpret data from the study&#xD;
&#xD;
          -  No use of any other experimental drug or therapy within 28 days of baseline&#xD;
&#xD;
          -  No known hypersensitivity to thalidomide&#xD;
&#xD;
          -  Patients who developed erythema nodosum if characterized by a desquamating rash while&#xD;
             taking thalidomide or similar drugs will be excluded&#xD;
&#xD;
          -  No prior use of lenalidomide&#xD;
&#xD;
          -  No concurrent use of other anti-cancer agents or treatments&#xD;
&#xD;
          -  No known positivity for HIV or infectious hepatitis, type B-8/9 or C&#xD;
&#xD;
          -  No active infection not controlled effectively with antimicrobial or antiviral therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Gabriela Chiorean, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University Melvin and Bren Simon Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>May 4, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <last_update_submitted>August 28, 2015</last_update_submitted>
  <last_update_submitted_qc>August 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

